Last reviewed · How we verify
Intanza
At a glance
| Generic name | Intanza |
|---|---|
| Also known as | Influenza Vaccine (Split Virion, Inactivated), Intanza, intradermal trivalent influenza vaccine |
| Sponsor | Dalhousie University |
| Modality | Biologic |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Comparison of Laser Assisted Epidermal to Intradermal Administration of Seasonal Influenza Vaccine (PHASE1)
- Imiquimod and Influenza Vaccine for Immunocompromised Patients (PHASE2)
- A Time-motion Study Comparing Self- to Nurse-vaccination With Influenza Vaccine (PHASE4)
- Immune Response of Intradermal and Intramuscular Preparations of Inactive Seasonal Influenza Vaccine in Older Age Group. (PHASE4)
- Vitamin D Supplementation and the Immune Response (PHASE2)
- Intradermal Versus Intramuscular Trivalent Influenza Vaccine in Adult Solid Organ Transplant Recipients (NA)
- Comparison of 4 Influenza Vaccines in Seniors (PHASE4)
- Intradermal Trivalent Influenza Vaccine With Imiquimod (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Intanza CI brief — competitive landscape report
- Intanza updates RSS · CI watch RSS
- Dalhousie University portfolio CI